SEARCH:   Advanced

Blood, 15 June 2005, Vol. 105, No. 12, pp. 4553-4560. Prepublished online as a Blood First Edition Paper on February 22, 2005; DOI 10.1182/blood-2004-12-4750. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-12-4750v1 105/12/4553    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Re, D. Articles by Diehl, V. Search for Related Content PubMed PubMed Citation Articles by Re, D. Articles by Diehl, V. Related Collections Immunobiology Neoplasia Reviews in Translational Hematology Free Research Articles Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  REVIEW IN TRANSLATIONAL HEMATOLOGY From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential Daniel Re, Roman K. Thomas, Karolin Behringer, and Volker Diehl From the Department I of Internal Medicine and The Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany; The Burnham Institute, John Reed Laboratory, La Jolla, CA; and the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Reclassification of Hodgkin disease as Hodgkin lymphoma (HL) represents a milestone in the lymphoma field, awarding recent insights in the molecular biology of Hodgkin and Reed-Sternberg (H-RS) cells and their environment. This review summarizes antiapoptotic and proproliferative pathways involved in the pathogenesis of this disease with the ultimate goal of translating laboratory knowledge into clinical decision making. The focus is on potential targets and novel drugs, which are discussed in the context of the complex biology of HL. Considering that HL patients are more likely to die from acute and late treatment-related toxicities than from HL itself, the introduction of targeted, biologically based therapies for HL patients with palliative and eventually curative intention might be justified. (Blood. 2005;105:4553-4560) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. Buglio, G. V. Georgakis, S. Hanabuchi, K. Arima, N. M. Khaskhely, Y.-J. Liu, and A. Younes Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines Blood, August 15, 2008; 112(4): 1424 - 1433. [Abstract] [Full Text] [PDF] V. Diehl Hodgkin's Disease -- From Pathology Specimen to Cure N. Engl. J. Med., November 8, 2007; 357(19): 1968 - 1971. [Full Text] [PDF] A. Diepstra, G. W. van Imhoff, H. E. Karim-Kos, A. van den Berg, G. J. te Meerman, M. Niens, I. M. Nolte, E. Bastiaannet, M. Schaapveld, E. Vellenga, et al. HLA Class II Expression by Hodgkin Reed-Sternberg Cells Is an Independent Prognostic Factor in Classical Hodgkin's Lymphoma J. Clin. Oncol., July 20, 2007; 25(21): 3101 - 3108. [Abstract] [Full Text] [PDF] S. J. Horning Risk, Cure and Complications in Advanced Hodgkin Disease Hematology, January 1, 2007; 2007(1): 197 - 203. [Abstract] [Full Text] [PDF] A. Sanchez-Aguilera, C. Montalban, P. de la Cueva, L. Sanchez-Verde, M. M. Morente, M. Garcia-Cosio, J. Garcia-Larana, C. Bellas, M. Provencio, V. Romagosa, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma Blood, July 15, 2006; 108(2): 662 - 668. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020